文献速递肝病

国际专家小组综述:resmetirom与semaglutide治疗MASH相关纤维化的临床实践更新

International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update.
PubMed 文献 · Gut · 2026-09-11

该国际专家小组综述整合了III期试验、FDA标签及新兴临床经验,针对MASH伴显著纤维化(F2-F3)且无肝硬化患者,提出resmetirom与semaglutide的治疗选择、启动、监测及应答评估框架。两种药物机制互补,综述涵盖基于无创检测的诊断至治疗全程管理,并给出个体化治疗及切换/联合的实践建议。

要点

  • resmetirom与semaglutide获FDA有条件批准,为首个用于MASH伴显著纤维化(F2-F3)无肝硬化的药物疗法。
  • 两药机制互补:resmetirom为肝脏靶向甲状腺激素受体β激动剂,semaglutide为GLP-1受体激动剂。
  • 综述提供基于无创检测的诊断、治疗选择、监测及应答评估的全程管理框架。

核心结论

  • resmetirom和semaglutide为MASH伴显著纤维化(F2-F3)无肝硬化患者提供了首个药物疗法,需按患者表型个体化选择并监测应答。

研究设计与样本

  • 国际专家小组综述,整合III期试验、FDA标签及新兴临床经验。

主要发现

  • resmetirom为肝脏靶向甲状腺激素受体β激动剂,semaglutide为GLP-1受体激动剂,两者机制互补。
  • 综述覆盖基于无创检测的MASH伴显著纤维化诊断、治疗选择与启动、治疗中监测及应答评估。

关键数值与推荐

  • FDA有条件批准resmetirom(Rezdiffra)和semaglutide(Wegovy)用于MASH伴显著纤维化(F2-F3)无肝硬化患者。
  • 提出定义应答、无应答及切换或联合用药标准的实践建议。

临床怎么用

  • 按患者表型个体化选择resmetirom或semaglutide,管理已使用GLP-1 RA的患者并评估应答。
  • 基于无创检测诊断MASH伴显著纤维化,启动治疗后定期监测并评估应答。

局限性

  • 框架需随长期结局数据及更多MASH疗法出现而更新。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The recent conditional US Food and Drug Administration (FDA) approval of two therapies, resmetirom (Rezdiffra) and semaglutide (Wegovy), marks the first time clinicians have pharmacological therapy for metabolic dysfunction-associated steatohepatitis (MASH) with significant fibrosis (F2-F3) without cirrhosis, a disease that previously had no available pharmacological treatment. The two agents act through complementary mechanisms: resmetirom as a liver-directed thyroid hormone receptor-beta agonist and semaglutide as a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a broad spectrum of metabolic effects. In this international expert panel review, we consolidate data from phase III trials, FDA labels and emerging clinical experience into a single resource. It covers the entire care pathway: non-invasive test-based diagnosis of MASH with significant fibrosis, treatment selection and initiation, on-treatment monitoring and response assessment. We offer practical recommendations for individualising therapy by patient phenotype, managing patients already receiving GLP-1 RAs and defining response, non-response and criteria for switching or combining agents. The proposed framework is intended to evolve as long-term outcomes data emerge and additional MASH therapies become available.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Mironova M, Ratziu V, Rinella ME, et al. International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update. Gut. 2026. PMID: 42728029. doi:10.1136/gutjnl-2026-340031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。